Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase EARLY_PHASE1 1Phase 4 1Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid cancer, medullary 1Carcinoma, Medullary 1

Interventions

Magnetic Resonance Spectroscopy 61Cyclophosphamide 57pembrolizumab 39fludarabine 38Radiotherapy 30Nivolumab 30Biopsy 27Metformin 23Fluorodeoxyglucose F18 22Bevacizumab 22Specimen Handling 21Temozolomide 18Cisplatin 18Radiosurgery 17Carboplatin 16Fluorouracil 15Paclitaxel 14Dexamethasone 14Radiation 13Gemcitabine 13Etoposide 13Rituximab 12Positron Emission Tomography Computed Tomography 12Letrozole 12Irinotecan 12gallium 68 PSMA-11 11durvalumab 11atezolizumab 11X-Rays 11Surgical Procedures, Operative 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Interventional × sacubitril and valsartan sodium hydrate drug combination × Clear all
NCT03647657 2022-02-10

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

University Hospital, Basel, Switzerland

Phase EARLY_PHASE1 Completed
8 enrolled
EndocrineHead & Neck

Thyroid cancer, medullary, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡